UCB SA (UCB.BR)

EUR 135.95

(-0.26%)

Operating Income Summary of UCB SA

  • UCB SA's latest annual operating income in 2023 was 604 Million EUR , down -30.25% from previous year.
  • UCB SA's latest quarterly operating income in 2024 Q2 was 323 Million EUR , down 0.0% from previous quarter.
  • UCB SA reported an annual operating income of 400 Million EUR in 2022, down -65.13% from previous year.
  • UCB SA reported an annual operating income of 1.14 Billion EUR in 2021, up 17.4% from previous year.
  • UCB SA reported a quarterly operating income of 479 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • UCB SA reported a quarterly operating income of 279 Million EUR for 2023 FY, down -30.25% from previous quarter.

Annual Operating Income Chart of UCB SA (2023 - 2002)

Historical Annual Operating Income of UCB SA (2023 - 2002)

Year Operating Income Operating Income Growth
2023 604 Million EUR -30.25%
2022 400 Million EUR -65.13%
2021 1.14 Billion EUR 17.4%
2020 977 Million EUR -9.87%
2019 1.08 Billion EUR -2.52%
2018 1.11 Billion EUR 3.44%
2017 1.07 Billion EUR 35.05%
2016 796 Million EUR 37.95%
2015 577 Million EUR 51.84%
2014 380 Million EUR 24.18%
2013 306 Million EUR -21.34%
2012 389 Million EUR 13.08%
2011 344 Million EUR 68.63%
2010 204 Million EUR -75.63%
2009 837 Million EUR 640.71%
2008 113 Million EUR -67.15%
2007 344 Million EUR -39.75%
2006 571 Million EUR 56.87%
2005 364 Million EUR -24.8%
2004 484.01 Million EUR -0.52%
2003 486.54 Million EUR -3.16%
2002 502.39 Million EUR 0.0%

Peer Operating Income Comparison of UCB SA

Name Operating Income Operating Income Difference
Nicox S.A. -17.5 Million EUR 3550.837%
European Medical Solutions -135 Thousand EUR 447507.407%
FERMENTALG -11.8 Million EUR 5215.176%
argenx SE -417.15 Million EUR 244.791%
BioSenic S.A. -7.04 Million EUR 8679.545%
Celyad Oncology SA -8.45 Million EUR 7242.013%
Hyloris Pharmaceuticals SA -15.99 Million EUR 3876.652%
Onward Medical N.V. -35.46 Million EUR 1803.184%
Oxurion NV -12.11 Million EUR 5087.614%
PHAXIAM Therapeutics S.A. -23.66 Million EUR 2652.832%
Financière de Tubize SA -2.14 Million EUR 28271.983%